Home / GLP-1 / Mounjaro / Prior authorization

Mounjaro · Prior authorization

Mounjaro prior authorization: how to get approved.

Mounjaro is approved for type 2 diabetes, and most plans cover it only after a prior authorization tied to that diagnosis. Here is what insurers commonly look for, the documentation to bring, and what to do if your request is denied.

Check my denial, free See the checklist

Denied already? We draft your appeal free, every citation checked against your plan's policy.

What it treats

Type 2 diabetes

FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Common bar

Diagnosis plus a prior drug

A documented type 2 diabetes diagnosis, A1c values, and often a trial of metformin first.

If denied

You can appeal

Internal review first, then independent external review. The deadline is on your denial notice.

What prior authorization for Mounjaro is

Mounjaro (tirzepatide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Because it is a higher-cost drug, most plans place it behind prior authorization: your prescriber sends the insurer a request, and the plan checks it against its published coverage policy before the pharmacy can dispense.

Prior authorization is not a judgment on whether you need the medicine. It is a documentation check tied to the approved use. The plans that approve fastest are the ones whose request showed the type 2 diabetes diagnosis, the glycemic values, and any prior therapy the policy asked for. The plans that deny usually do so because the diagnosis or a required step was not documented, or because the request was framed for a use Mounjaro is not approved for.

What insurers commonly look for

Each plan publishes its own coverage policy, and the exact rules differ. That said, most Mounjaro criteria are built around the type 2 diabetes indication and a few recurring documentation patterns. Expect a policy to ask for some combination of:

  • A documented type 2 diabetes diagnosis. This is the anchor. The diagnosis should be in the chart with its supporting basis, not just listed.
  • Recent glycemic values. Many policies want a recent A1c or other lab values that show why the therapy is needed and how it fits your management.
  • Step therapy, on many plans. A common requirement is a documented trial of metformin or another first-line therapy before Mounjaro, or a reason it was not appropriate. If you have that history, it belongs in the request.
  • Formulary tier and quantity. Mounjaro sits on a formulary tier, and some plans apply quantity limits. A request that matches the approved dosing avoids an easy denial.
  • Not for weight loss. Mounjaro is not FDA-approved for weight loss. A request framed for weight loss is off-label, and most plans deny it on that basis. Tirzepatide is also sold as Zepbound, which is approved for chronic weight management, a more direct path if weight is the goal.

Important: the bullets above are the general pattern, drawn from the FDA label and how coverage policies are typically structured. They are not any one insurer's exact criteria. The specific labs, codes, and required forms that actually bind your request live in your plan's own published policy. Read that policy, or have your prescriber pull it, before you submit.

The documentation to bring

Give your prescriber a clean packet and the request goes through faster. A strong Mounjaro prior authorization usually includes:

  • The type 2 diabetes diagnosis, with its date and supporting basis in the chart.
  • Recent A1c or other glycemic lab values, and earlier readings if you have them.
  • If your plan requires step therapy, the record of metformin or another prior therapy, including any reason it was stopped or not appropriate.
  • Any other diabetes therapies you take, since Mounjaro is studied as monotherapy and alongside common diabetes medicines.
  • The plan's completed prior authorization form for the medicine, signed by your prescriber.

Care decisions, including whether Mounjaro is right for you, stay between you and your prescriber. AppealIt does not provide medical advice.

What to do if your prior authorization is denied

A denied prior authorization is not a final no. Under the Affordable Care Act, you have the right to a full internal appeal with your plan, and if that is upheld, an independent external review by a reviewer outside the insurer. The move that works is precision: get the exact policy the plan applied, then show, point by point, where your records meet each criterion it lists, starting with the type 2 diabetes diagnosis.

  • Read the denial reason. If it says off-label or step therapy, that tells you exactly what the appeal has to answer.
  • Map your records to the policy. If the denial was off-label and you do have type 2 diabetes, the diagnosis and labs are the heart of the appeal. If it was step therapy, attach the prior-therapy history.
  • File before the deadline. The window is stated on your denial notice, often between 60 and 180 days. The notice controls, so check it.
  • Escalate if upheld. If the internal appeal is denied, request the independent external review. A reviewer outside the plan takes a fresh look.

See the full walkthrough on our Mounjaro denial and appeal guide, or jump straight to a read on your odds.

The magic is visible

If you are appealing, your draft is built from your plan's own rules. Every citation checked.

We draft from the sources below, then verify each one before you file. On our held-out testing: 0 invented citations, versus about 1 in 4 for raw AI.

  • Your plan's coverage policyThe specific prior authorization criteria for GLP-1 therapies that apply to your planVerified
  • FDA labelTirzepatide (Mounjaro) prescribing information, type 2 diabetes indication and dosingVerified
  • Your recordsYour type 2 diabetes diagnosis, A1c values, and prior therapies, cited back accuratelyVerified

Denied, or bracing for it? Let's check your odds, free.

Answer a few questions for an honest read on your case, then your verified draft. No account, no cost.

Check my denial, free

Mounjaro prior authorization: common questions

What do insurers usually require to approve Mounjaro?
Mounjaro is FDA-approved to improve glycemic control in adults with type 2 diabetes, so most plans build their criteria around that: a documented type 2 diabetes diagnosis, recent A1c or other glycemic values, and often a trial of metformin or another first-line therapy first. The exact rules live in your plan's published policy, so read it before you submit.
Will insurance cover Mounjaro for weight loss?
Mounjaro's FDA approval is for type 2 diabetes, not weight loss. A request submitted for weight loss is off-label, which most plans deny. Tirzepatide is also sold as Zepbound, which is FDA-approved for chronic weight management, so if weight is the goal that can be a more direct path. Your prescriber can advise. We do not provide medical advice.
What if I was denied for step therapy?
Step therapy means the plan wants a documented trial of a first-line option such as metformin before Mounjaro, or a reason it was not appropriate. If you have already tried and failed an earlier therapy, that history is the core of the appeal. Attach the record and tie it to the policy's step-therapy language.
What if my prior authorization is denied?
A denial is not the end. You have the right to an internal appeal with your plan, then an independent external review if that is upheld. The winning move is to map your records to the exact policy criteria the plan cited, including your diagnosis and any required prior therapy. We draft that appeal for free, grounded in your plan's own rules with every citation verified. AppealIt is not a law firm and does not provide legal or medical advice.

If you are already denied: All Mounjaro denials · UnitedHealthcare · Cigna · Aetna